Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium
07 Ottobre 2024 - 2:00PM
Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company
reimagining therapeutic delivery, today announced that company
leadership will present at the 19th Annual Peptide Therapeutics
Symposium, taking place virtually and in person in La Jolla,
California, October 22–23, 2024. Details of the presentation are as
follows:
Presentation Title: |
Empowering Peptide Self-Administration with Needle Free Smart
Capsules |
Date &
Time: |
October 22, 2024, 2:30 PM – 3:00
PM PT |
Presenter: |
Sharat Singh, PhD, Head of
Research, Biora Therapeutics |
|
|
The Peptide Therapeutics Symposium brings together world leaders
in peptide research from academia and the biopharmaceutical
industries who are focused on advances in core technology pertinent
to peptide-based drug discovery and therapeutic candidate
development.
About Biora TherapeuticsBiora
Therapeutics is a clinical-stage biotech company developing two
smart pill-based therapeutics platforms: the NaviCap™ platform for
colon-targeted treatment of IBD, designed to improve patient
outcomes through treatment at the site of disease in the
gastrointestinal tract, and the BioJet™ platform for oral delivery
of large molecules, designed to replace injection with needle-free,
oral delivery for better management of chronic diseases.
For more information, visit bioratherapeutics.com
or follow the company on LinkedIn or X.
Safe Harbor Statement or Forward-Looking
StatementsThis press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995, which
statements are subject to substantial risks and uncertainties and
are based on estimates and assumptions. All statements, other than
statements of historical facts included in this press release,
including statements concerning the progress and future
expectations and goals of our research and development, preclinical
and clinical trial activities, including those involving BT-600 and
our NaviCap platform and model-based data projections for the
BT-600 program, and partnering and collaboration efforts with third
parties, are forward-looking statements. In some cases, you can
identify forward-looking statements by terms such as “envision,”
“may,” “might,” “will,” “objective,” “intend,” “should,” “could,”
“can,” “would,” “expect,” “anticipate,” “forward,” “believe,”
“design,” “estimate,” “predict,” “projects,” “projecting,”
“potential,” “plan,” “goal(s),” “target,” or the negative of these
terms, and similar expressions intended to identify forward-looking
statements. These statements reflect our plans, estimates, and
expectations, as of the date of this press release. These
statements involve known and unknown risks, uncertainties and other
factors that could cause our actual results to differ materially
from the forward-looking statements expressed or implied in this
press release. Such risks, uncertainties, and other factors
include, among others, our ability to innovate in the field of
therapeutics, our ability to make future FDA filings and initiate
and execute clinical trials on expected timelines or at all, our
ability to obtain and maintain regulatory approval or clearance of
our products on expected timelines or at all, our plans to
research, develop, and commercialize new products, the
unpredictable relationship between preclinical study results and
clinical study results, our expectations regarding allowed patents
or intended grants to result in issued or granted patents, our
expectations regarding opportunities with current or future
pharmaceutical collaborators or partners, our ability to raise
sufficient capital to achieve our business objectives, our ability
to maintain our listing on the Nasdaq Global Market, and those
risks described in “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” in our
Annual Report on Form 10-K for the year ended December 31, 2023
filed with the Securities and Exchange Commission (SEC) and other
subsequent documents, including Quarterly Reports on Form 10-Q,
that we file with the SEC.
Biora Therapeutics expressly disclaims any
obligation to update any forward-looking statements whether as a
result of new information, future events or otherwise, except as
required by law.
Investor ContactChuck
PadalaManaging Director, LifeSci AdvisorsIR@bioratherapeutics.com
(646) 627-8390
Media ContactLiz RobinsonCG
Lifelrobinson@cglife.com
Grafico Azioni Biora Therapeutics (NASDAQ:BIOR)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Biora Therapeutics (NASDAQ:BIOR)
Storico
Da Ott 2023 a Ott 2024